Medicare High-Value Drug List Model Could Lower Out-Of-Pocket Costs for 4 in 10 Beneficiaries

AJMC September 23, 2024
Brooke McCormick

The proposed Medicare High-Value Drug List Model, also known as the Medicare $2 Drug List, could have modestly reduced out-of-pocket costs for 38% of beneficiaries if implemented in 2021.

The Medicare High-Value Drug List Model could have modestly lowered out-of-pocket spending for 4 in 10 Medicare beneficiaries if implemented in 2021, according to a research letter published in JAMA Internal Medicine.¹

CMS proposed the Medicare High-Value Drug List Model, or the Medicare $2 Drug List, in 2023.² This model would encourage Medicare Part D drug plans to voluntarily cap out-of-pocket costs at $2 per month for a standardized list of 150 generic drugs.¹ Consequently, the researchers conducted a study to estimate potential savings from this policy.

To do so, they...

Today's Sponsors

Today's Sponsor